Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02040831 · ClinicalTrials.gov registry record · Phase 1

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

A Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
3
Enrollment target
1
Study location

NCT02040831: Completed Phase 1 study of Respiratory Syncytial Virus Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT02040831 is a Phase 1 study of Respiratory Syncytial Virus Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3 participants, below the 1,091-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02040831, a Phase 1 study of Respiratory Syncytial Virus Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children. This study is a companion study to IMPAACT 2000.

Conditions Studied

Respiratory Syncytial Virus Infections

Interventions

  • BIOLOGICAL RSV LID ΔM2-2 Vaccine
  • BIOLOGICAL Placebo Vaccine

Study Locations (1)

Maryland

  • Center for Immunization Research, JHU - Baltimore

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2014-09
Est. Completion 2015-04
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT02040831 record still lists

NCT02040831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,091-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which RSV LID ΔM2-2 Vaccine is the first listed.

NCT02040831 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02040831 about?

NCT02040831 is a clinical study titled "Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children". Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children. This study is a companion study to IMPAACT 2000.

What is the current status of trial NCT02040831?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-09. Estimated completion is 2015-04.

What conditions does trial NCT02040831 study?

This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.

What interventions are being tested in trial NCT02040831?

The interventions under investigation include: RSV LID ΔM2-2 Vaccine (BIOLOGICAL), Placebo Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02040831?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02040831 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Respiratory Syncytial Virus Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02040831's enrollment target sits among peer trials

3 22nd of 21 the lowest of 21 other Respiratory Syncytial Virus Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02040831, the US trial registry maintained by the National Library of Medicine. NCT02040831 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.